Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress in testing.

P J Upman1

  • 1NAMSA, 2261 Tracy Road, Northwood, Ohio 43619, USA. pupman@namsa.com

Medical Device Technology
|August 27, 2003
PubMed
Summary

ISO 10993, Part 4, is being revised to update how medical devices interact with blood. These changes will significantly alter the nonclinical compatibility testing approach for medical devices.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacologic and toxicologic profile of chymopapain B (Chemolase).

Drug and chemical toxicologyยท1984
See all related articles

Area of Science:

  • Biomedical Engineering
  • Materials Science
  • Toxicology

Background:

  • Medical devices interacting with blood require rigorous biological evaluation.
  • Current standards for assessing blood compatibility are undergoing revision.
  • ISO 10993, Part 4, specifically addresses tests for blood-contacting devices.

Purpose of the Study:

  • To inform stakeholders about upcoming revisions to ISO 10993, Part 4.
  • To highlight the significant changes in selecting tests for medical device blood compatibility.
  • To prepare the medical device industry for updated nonclinical testing requirements.

Main Methods:

  • Analysis of the revised ISO 10993, Part 4 draft.
  • Comparison of current and proposed testing methodologies for blood interactions.
  • Identification of key changes in test selection criteria.

Main Results:

  • The revision introduces a new framework for selecting blood compatibility tests.
  • Specific test recommendations will be updated based on device characteristics and contact duration.
  • Emphasis on a risk-based approach to biological evaluation.

Conclusions:

  • The upcoming revision of ISO 10993, Part 4, necessitates a re-evaluation of current testing strategies.
  • Manufacturers must adapt their nonclinical compatibility assessments to align with the revised standard.
  • Proactive understanding of these changes is crucial for regulatory compliance and patient safety.

Related Experiment Videos